NCT05629923View on ClinicalTrials.gov

EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS

CompletedOBSERVATIONAL
Enrollment

306

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

November 1, 2022

Study Completion Date

November 30, 2022

Conditions
COVID-19 PandemicTransplant-Related Disorder
Interventions
DRUG

tixagevimab-cilgavimab(AZD7442, AstraZeneca)

In the case of antibody level \<100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca).

Trial Locations (1)

00133

Università degli Studi di Roma Tor Vergata, Roma

All Listed Sponsors
lead

University of Rome Tor Vergata

OTHER